Britain and America have finalized a significant trade agreement that will ensure zero duties on UK medicine exports going into the American market.
The Terms of the Deal
As part of the deal, the UK has committed to increase spending on medicines through the public health system. This move ensures that tariffs on these key goods will be held at zero for a period of the next three years.
This development follows earlier statements to hike import taxes on branded drug imports, with increases floated up to one hundred percent.
"This deal with the UK bolsters the international landscape for cutting-edge drugs and establishes much-needed fairness to transatlantic pharmaceutical trade," a statement noted.
Commercial Impact
Medicines represent one of the UK's most significant export categories to the United States, which is by far the largest destination for major British pharmaceutical firms.
Statistics indicate that in the one-year period prior to last September, the UK shipped drugs totaling £11.1bn to the US. This value made up a significant portion of British export trade in that timeframe.
"This guarantee secures employment, increases capital expenditure and facilitates the UK to establish itself as a international leader for medical research," the Business and Trade Secretary remarked.
Specific NHS Changes
The deal involves several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to raise total public funding on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Rebate Cap: The percentage pharmaceutical firms must return to the NHS to stay within budget will be capped at 15%. Last year, rebates exceeded 20%.
Recent Tensions
The deal comes amid a long-running tension between the sector and the British authorities over spending levels and approval rates.
These tensions were exacerbated by claims that US consumers were charged a premium for the identical medicines than patients in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been paused or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
One official acknowledged that the NHS had to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the past decade.
